Farallon Capital Management LLC Has $18.38 Million Stake in Savara Inc (NASDAQ:SVRA)

Farallon Capital Management LLC grew its position in Savara Inc (NASDAQ:SVRA) by 90.5% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 4,560,000 shares of the company’s stock after buying an additional 2,165,701 shares during the quarter. Farallon Capital Management LLC owned 3.30% of Savara worth $18,377,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. ProShare Advisors LLC increased its stake in Savara by 9.0% in the first quarter. ProShare Advisors LLC now owns 25,715 shares of the company’s stock valued at $128,000 after acquiring an additional 2,114 shares during the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of Savara by 15.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 33,692 shares of the company’s stock worth $168,000 after buying an additional 4,625 shares in the last quarter. Principal Financial Group Inc. lifted its position in shares of Savara by 64.4% during the 2nd quarter. Principal Financial Group Inc. now owns 17,795 shares of the company’s stock worth $72,000 after buying an additional 6,973 shares during the last quarter. CANADA LIFE ASSURANCE Co acquired a new stake in Savara in the first quarter valued at about $35,000. Finally, ClariVest Asset Management LLC increased its position in Savara by 2.9% during the 2nd quarter. ClariVest Asset Management LLC now owns 256,479 shares of the company’s stock worth $1,034,000 after purchasing an additional 7,170 shares in the last quarter. Institutional investors own 87.93% of the company’s stock.

Savara Stock Up 2.7 %

Savara stock opened at $4.61 on Tuesday. Savara Inc has a 12-month low of $3.12 and a 12-month high of $5.70. The company has a quick ratio of 11.31, a current ratio of 11.31 and a debt-to-equity ratio of 0.26. The company has a market capitalization of $637.05 million, a PE ratio of -12.46 and a beta of 0.97. The firm’s fifty day moving average is $4.38 and its 200 day moving average is $4.48.

Savara (NASDAQ:SVRA) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.01). As a group, sell-side analysts predict that Savara Inc will post -0.44 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have weighed in on SVRA. JMP Securities reissued a “market outperform” rating and set a $9.00 target price on shares of Savara in a report on Monday, September 9th. Oppenheimer boosted their price objective on shares of Savara from $11.00 to $15.00 and gave the stock an “outperform” rating in a research note on Wednesday, June 26th. HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of Savara in a report on Wednesday, August 14th. Finally, Guggenheim lifted their target price on Savara from $8.00 to $10.00 and gave the stock a “buy” rating in a report on Thursday, June 27th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $11.17.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.